デフォルト表紙
市場調査レポート
商品コード
1451731

抗てんかん薬市場:世代別、抗てんかん薬タイプ別、流通チャネル別、地域別、2024-2032

Epilepsy Drugs Market by Generation Type, Anti-Epileptics Drugs Type, Distribution Channel, and Region 2024-2032

出版日: | 発行: IMARC | ページ情報: 英文 145 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
抗てんかん薬市場:世代別、抗てんかん薬タイプ別、流通チャネル別、地域別、2024-2032
出版日: 2024年03月02日
発行: IMARC
ページ情報: 英文 145 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗てんかん薬の世界市場規模は2023年に23億米ドルに達しました。今後、IMARC Groupは、2024~2032年の成長率(CAGR)は7.16%で、2032年には44億米ドルに達すると予測しています。てんかんの有病率の上昇、老年人口における脳腫瘍の発生率の増加、広範な研究開発(R&D)活動は、市場を牽引する主な要因のひとつです。

抗てんかん薬とは、てんかんの治療に使用される薬剤のことであり、てんかんは、予測不能で、誘発性のない、再発性の発作を引き起こす中枢神経系(CNS)疾患です。てんかんは様々な精神的・身体的機能に影響を及ぼし、突然の行動変化、感覚、意識の喪失、深刻な精神的苦痛を引き起こします。抗てんかん薬には、錠剤、カプセル剤、液剤、シロップ剤などの第一世代、第二世代、第三世代の抗てんかん薬(AED)があり、経口投与、静脈内投与、筋肉内投与が行われています。抗てんかん薬は、部分発作、難治性発作、混合発作、強直間代発作、急性反復発作など、さまざまな発作の治療に広く用いられています。抗てんかん薬は安全で、忍容性が高く、生命を脅かす副作用を防ぎ、認知機能への悪影響を最小限に抑えることができます。

現在、神経疾患、出産関連傷害、感染症、薬物乱用、交通事故などの増加によりてんかんの有病率が上昇していることが、市場の成長を促す主な要因の一つとなっています。抗てんかん薬は、発作の除去、発作頻度の減少、長期治療に伴う副作用の回避のために広く使用されており、患者が通常の心理社会的・職業的活動を回復し、通常のライフスタイルを維持するのに役立っています。これに加えて、発作の原因となる脳腫瘍などの重大な病気を発症しやすい老年人口の増加が、もう一つの大きな成長促進要因として作用しています。さらに、手頃な価格で、副作用が少なく忍容性と有効性が改善された新薬や先進薬の開発に向けた広範な研究開発(R&D)活動は、現在、市場成長にプラスの影響を与えています。これとは別に、血清中薬物濃度の変動を最小限に抑えながら投与間隔を長くできる徐放性(ER)製剤が最近開発され、即放性(IR)製剤に比べて有効性と服薬アドヒアランスが向上したことが、市場の成長を促進しています。さらに、この疾患について大衆を啓蒙し、研究を促進し、より良い治療選択肢を迅速化することで積極的な支援を提供するための様々な政府イニシアチブの実施が、市場の成長を促進しています。その他にも、新薬の認可の高まり、ヘルスケアインフラ施設の急速な改善、神経疾患の利用可能な治療法に関する一般市民の意識の高まり、てんかんにまつわるスティグマの減少などが、市場の成長を後押しすると予測されています。

本レポートで扱う主な質問

  • 抗てんかん薬の世界市場はこれまでどのように推移し、今後どのように推移していくのか?
  • 抗てんかん薬の世界市場における市場促進要因、市場抑制要因、市場機会は何か?
  • 主要な地域市場は?
  • 最も魅力的な抗てんかん薬市場はどの国か?
  • 世代別の市場内訳は?
  • 抗てんかん薬のタイプ別市場内訳は?
  • 流通チャネル別の市場内訳は?
  • 抗てんかん薬の世界市場における競合構造は?
  • 抗てんかん薬の世界市場における主要プレイヤー/企業は?

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 抗てんかん薬の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳:世代タイプ別

  • 第一世代医薬品
    • 市場動向
    • 主要セグメント
      • フェニトイン
      • カルバマゼピン
      • オクスカルバゼピン
      • バルプロ酸塩
      • エトスクシミド
      • プリミドン
      • フェノバルビタール
    • 市場予測
  • 第二世代医薬品
    • 市場動向
    • 主要セグメント
      • レベチラセタム
      • ラモトリギン
      • トピラマート
      • プレガバリン
      • ルフィナミド
      • ゾニサミド
    • 市場予測
  • 第三世代医薬品
    • 市場動向
    • 主要セグメント
      • ラコサミド
      • ペランパネル
      • エスリカルバゼピン酢酸塩
      • エゾガビン/レチガビン
    • 市場予測

第7章 市場内訳:抗てんかん薬タイプ別

  • ナロースペクトルAED
    • 市場動向
    • 市場予測
  • 広域型AED
    • 市場動向
    • 市場予測

第8章 市場内訳:流通チャネル別

  • 病院薬局
    • 市場動向
    • 市場予測
  • 薬局店舗
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳:地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳:国別
    • 市場予測

第10章 促進要因、抑制要因、機会

  • 市場概要
  • 促進要因
  • 抑制要因
  • 機会

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Alkem Laboratories Limited
    • Bausch Health Companies Inc.
    • Eisai Co. Ltd.
    • GSK plc
    • H. Lundbeck A/S
    • Jazz Pharmaceuticals plc
    • Novartis AG
    • Pfizer Inc.
    • Sunovion Pharmaceuticals Inc.(Sumitomo Dainippon Pharma Co. Ltd.)
    • UCB S.A.
図表

List of Figures

  • Figure 1: Global: Epilepsy Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Epilepsy Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Epilepsy Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Epilepsy Drugs Market: Breakup by Generation Type (in %), 2023
  • Figure 5: Global: Epilepsy Drugs Market: Breakup by Anti-Epileptics Drugs Type (in %), 2023
  • Figure 6: Global: Epilepsy Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Epilepsy Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Epilepsy Drugs (First Generation Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Epilepsy Drugs (First Generation Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Epilepsy Drugs (Second Generation Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Epilepsy Drugs (Second Generation Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Epilepsy Drugs (Third Generation Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Epilepsy Drugs (Third Generation Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Epilepsy Drugs (Narrow-Spectrum AEDs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Epilepsy Drugs (Narrow-Spectrum AEDs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Epilepsy Drugs (Broad-Spectrum AEDs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Epilepsy Drugs (Broad-Spectrum AEDs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Epilepsy Drugs (Hospital Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Epilepsy Drugs (Hospital Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Epilepsy Drugs (Pharmacy Stores) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Epilepsy Drugs (Pharmacy Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Epilepsy Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Epilepsy Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: North America: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: North America: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: United States: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: United States: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Canada: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Canada: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Asia-Pacific: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Asia-Pacific: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: China: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: China: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Japan: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Japan: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: India: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: India: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: South Korea: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: South Korea: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Australia: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Australia: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Indonesia: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Indonesia: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Others: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Others: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Europe: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Europe: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Germany: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Germany: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: France: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: France: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: United Kingdom: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: United Kingdom: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Italy: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Italy: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Spain: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Spain: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Russia: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Russia: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Others: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Others: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Latin America: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Latin America: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Brazil: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Brazil: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Mexico: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Mexico: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Others: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Others: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Middle East and Africa: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Middle East and Africa: Epilepsy Drugs Market: Breakup by Country (in %), 2023
  • Figure 72: Middle East and Africa: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Global: Epilepsy Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 74: Global: Epilepsy Drugs Industry: Value Chain Analysis
  • Figure 75: Global: Epilepsy Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Epilepsy Drugs Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Epilepsy Drugs Market Forecast: Breakup by Generation Type (in Million US$), 2024-2032
  • Table 3: Global: Epilepsy Drugs Market Forecast: Breakup by Anti-Epileptics Drugs Type (in Million US$), 2024-2032
  • Table 4: Global: Epilepsy Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Epilepsy Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Epilepsy Drugs Market: Competitive Structure
  • Table 7: Global: Epilepsy Drugs Market: Key Players
目次
Product Code: SR112024A6650

The global epilepsy drugs market size reached US$ 2.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.4 Billion by 2032, exhibiting a growth rate (CAGR) of 7.16% during 2024-2032. The rising prevalence of epilepsy, increasing incidences of brain cancer in the geriatric population, and extensive research and development (R&D) activities represent some of the key factors driving the market.

Epilepsy drugs refer to medications used for treating epilepsy, a central nervous system (CNS) disorder that causes unpredictive, unprovoked, and recurrent episodes of seizures. Epilepsy affects various mental and physical functions causing sudden behavioral changes, sensations, loss of awareness, and severe emotional distress. Its medication includes first-, second-, and third-generation anti-epileptic drugs (AEDs), such as tablets, capsules, liquids, and syrups that are administered through oral, intravenous (IV), and intramuscular routes. Epilepsy drugs are widely used to treat various seizures, including partial onset, hard-to-treat, mixed, tonic-clonic, and acute repetitive seizures. Epilepsy drugs are safe, offer better tolerability, prevent life-threatening adverse effects, and minimize the negative impact on the cognitive functions.

At present, the rising prevalence of epilepsy due to increasing incidences of neurological disorders, birth-related injuries, infections, substance abuse, and road injuries is one of the primary factors driving the market growth. Epilepsy drugs are widely used to eliminate seizures, reduce their frequency, and evade the adverse effects associated with long-term treatments, thus helping patients in restoring their usual psychosocial and vocational activities and maintaining a normal lifestyle. In addition to this, the rising geriatric population that is prone to developing critical ailments, such as brain cancer, that can cause seizures, is acting as another major growth-inducing factor. Furthermore, extensive research and development (R&D) activities toward developing new and advanced drugs that are affordable and provide improved tolerability and efficacy with fewer side effects are currently positively influencing the market growth. Apart from this, the recent development of extended-release (ER) drug formulations that allow longer dosing intervals while minimizing the fluctuations in serum drug levels, thus improving efficacy and adherence as compared to immediate-release (IR) drugs, is facilitating the market growth. Moreover, the implementation of various government initiatives to educate the masses about the disorder, promote research, and provide active support by expediting better treatment options are propelling the market growth. Other factors, including the rising approval of novel drugs, rapid improvements in healthcare infrastructural facilities, increasing public awareness regarding the available treatments of neurological disorders, and the decreasing stigma associated with epilepsy, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global epilepsy drugs market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on generation type, anti-epileptics drugs type and distribution channel.

Generation Type Insights

First Generation Drugs

Phenytoin

Carbamazepine

Oxcarbazepine

Valproate

Ethosuximide

Primidone

Phenobarbital

Second Generation Drugs

Levetiracetam

Lamotrigine

Topiramate

Pregabalin

Rufinamide

Zonisamide

Third Generation Drugs

Lacosamide

Perampanel

Eslicarbazepine Acetate

Ezogabine/Retigabine

The report has also provided a detailed breakup and analysis of the epilepsy drugs market based on the generation type. This includes first generation drugs (phenytoin, carbamazepine, oxcarbazepine, valproate, ethosuximide, primidone, and phenobarbital), second generation drugs (levetiracetam, lamotrigine, topiramate, pregabalin, rufinamide, and zonisamide), and third generation drugs (lacosamide, perampanel, eslicarbazepine acetate, and ezogabine/retigabine). According to the report, second generation drugs represented the largest segment.

Anti-Epileptics Drugs Type Insights

Narrow-Spectrum AEDs

Broad-Spectrum AEDs

A detailed breakup and analysis of the epilepsy drugs market based on the anti-epileptics drugs type has also been provided in the report. This includes narrow and broad-spectrum AEDs. According to the report, broad-spectrum AEDs accounted for the largest market share.

Distribution Channel Insights

Hospital Pharmacy

Pharmacy Stores

Others

A detailed breakup and analysis of the epilepsy drugs market based on the distribution channel has been provided in the report. This includes hospital pharmacy, pharmacy stores, and others. According to the report, hospital pharmacy accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for epilepsy drugs. Some of the factors driving the North America epilepsy drugs market growth include increasing burden of epilepsy, rising awareness campaigns, launching of new products, etc.

Competitive Landscape

The report has also provided a comprehensive analysis of the competitive landscape in the global epilepsy drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Alkem Laboratories Limited, Bausch Health Companies Inc., Eisai Co. Ltd., GSK plc, H. Lundbeck A/S, Jazz Pharmaceuticals plc, Novartis AG, Pfizer Inc., Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd.), UCB S.A., etc. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global epilepsy drugs market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global epilepsy drugs market?
  • What are the key regional markets?
  • Which countries represent the most attractive epilepsy drugs markets?
  • What is the breakup of the market based on the generation type?
  • What is the breakup of the market based on the anti-epileptics drugs type?
  • What is the breakup of the market based on the distribution channel?
  • What is the competitive structure of the global epilepsy drugs market?
  • Who are the key players/companies in the global epilepsy drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Epilepsy Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Generation Type

  • 6.1 First Generation Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Phenytoin
      • 6.1.2.2 Carbamazepine
      • 6.1.2.3 Oxcarbazepine
      • 6.1.2.4 Valproate
      • 6.1.2.5 Ethosuximide
      • 6.1.2.6 Primidone
      • 6.1.2.7 Phenobarbital
    • 6.1.3 Market Forecast
  • 6.2 Second Generation Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Levetiracetam
      • 6.2.2.2 Lamotrigine
      • 6.2.2.3 Topiramate
      • 6.2.2.4 Pregabalin
      • 6.2.2.5 Rufinamide
      • 6.2.2.6 Zonisamide
    • 6.2.3 Market Forecast
  • 6.3 Third Generation Drugs
    • 6.3.1 Market Trends
    • 6.3.2 Key Segments
      • 6.3.2.1 Lacosamide
      • 6.3.2.2 Perampanel
      • 6.3.2.3 Eslicarbazepine Acetate
      • 6.3.2.4 Ezogabine/Retigabine
    • 6.3.3 Market Forecast

7 Market Breakup by Anti-Epileptics Drugs Type

  • 7.1 Narrow-Spectrum AEDs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Broad-Spectrum AEDs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Pharmacy Stores
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Alkem Laboratories Limited
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bausch Health Companies Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eisai Co. Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 GSK plc
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 H. Lundbeck A/S
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Jazz Pharmaceuticals plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Novartis AG
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Pfizer Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd.)
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 SWOT Analysis
    • 14.3.11 UCB S.A.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report